Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine
- 1 March 1993
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 11 (3) , 251-255
- https://doi.org/10.1016/0731-7085(93)80205-f
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Recent Developments in Hepatic Drug OxidationClinical Pharmacokinetics, 1990
- Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteersClinical Pharmacology & Therapeutics, 1989
- Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1989
- Oral Tyramine Pressor Test and the Safety of Monoamine Oxidase Inhibitor DrugsJournal of Clinical Psychopharmacology, 1988
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralolEuropean Journal of Clinical Pharmacology, 1985
- Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.British Journal of Clinical Pharmacology, 1982
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980